معرفی
Jack W. Lipton is a Professor and Chair of Translational Science and Molecular Medicine at Michigan State University (MSU) College of Human Medicine. He holds concurrent appointments as Teaching Faculty in MSU's Neuroscience Program and Associate Dean for Research Analytics. His career spans leadership roles at Rush University Medical Center and University of Cincinnati before joining MSU in 2009.
- B.A. in Psychology, UC Berkeley (1988)
- Ph.D. in Behavioral Neuroscience, UCLA (1993)
- Postdoctoral Fellowship, Rush Children's Hospital
Dr. Lipton's research focuses on developmental neurotoxicology and translational Parkinson's disease models. His work examines gestational drug exposure effects, including MDMA-induced dopamine neuron sprouting, and develops therapeutic strategies like neural transplantation, gene therapy, and deep brain stimulation. Current projects investigate alpha-synuclein pathology, Nurr1 gene regulation, and saliva-based SARS-CoV-2 testing protocols.
Prominent scientific achievements include continuous NIH funding since 1993, the Morris K. Udall Center of Excellence in Parkinson's Research, and over 50 publications. His lab's 2025 study on alpha-synuclein fibrils and 2022 saliva testing framework demonstrate methodological innovation.
Scientific Awards:
- NIH/NIDA R01 grants
- NIH/NINDS funding
- Michael J. Fox Foundation awards
- Morris K. Udall Center leadership
- 2024 NIH grant for saliva diagnostics
Dr. Lipton's technical expertise spans neuronal culture, ELISA, mass spectrometry, PCR arrays, and stereotaxic surgery. His lab collaborates with Drs. Timothy Collier, Caryl Sortwell, and Kathy Steece-Collier on Parkinson's disease mechanisms. Recent initiatives include federal regulatory advocacy for university-based pandemic testing and op-eds in Wall Street Journal and Washington Post.
